Should I buy or sell SpringWorks Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares. View SWTX analyst ratings or view top-rated stocks .

What is SpringWorks Therapeutics' stock price target for 2024?

4 equities research analysts have issued 1-year price objectives for SpringWorks Therapeutics' shares. Their SWTX share price targets range from $41.00 to $64.00. On average, they expect the company's stock price to reach $51.80 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price. View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts .

How have SWTX shares performed in 2023?

SpringWorks Therapeutics' stock was trading at $26.01 at the beginning of 2023. Since then, SWTX shares have increased by 17.6% and is now trading at $30.60. View the best growth stocks for 2023 here .

When is SpringWorks Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our SWTX earnings forecast .

How were SpringWorks Therapeutics' earnings last quarter?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.31) by $0.04.

What ETFs hold SpringWorks Therapeutics' stock?

ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO) . Virtus LifeSci Biotech Clinical Trials ETF (BBC) .

What other stocks do shareholders of SpringWorks Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM) , Dicerna Pharmaceuticals (DRNA) , Johnson & Johnson (JNJ) , Albireo Pharma (ALBO) , Gilead Sciences (GILD) , Sunrun (RUN) , Alnylam Pharmaceuticals (ALNY) , Aptevo Therapeutics (APVO) , Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI) .

When did SpringWorks Therapeutics IPO?

(SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are SpringWorks Therapeutics' major shareholders?

SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Fiera Capital Corp (1.43%), JPMorgan Chase & Co. (0.91%), Northern Trust Corp (0.83%), Charles Schwab Investment Management Inc. (0.68%) and Massachusetts Financial Services Co. MA (0.65%). Insiders that own company stock include Badreddin Edris , Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith , Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto . View institutional ownership trends .

How do I buy shares of SpringWorks Therapeutics?

Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does SpringWorks Therapeutics have any subsidiaries?

The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc.. Read More

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

$30.56

-0.94 (-2.98%)

(As of 11:10 AM ET)

Compare

Today's Range: $30.14
▼
$31.56
50-Day Range: $18.94
▼
$31.90
52-Week Range: $18.00
▼
$34.16

Volume: 485,107 shs
Average Volume: 739,398 shs
Market Capitalization: $1.91 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.80

SpringWorks Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 69.3% Upside
$51.80 Price Target
Short Interest: Bearish
20.39% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.29
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.13) to ($4.66) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

736th out of 942 stocks

Biological Products, Except Diagnostic Industry

124th out of 157 stocks

3.5

Analyst's Opinion

Consensus Rating
SpringWorks Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.80, SpringWorks Therapeutics has a forecasted upside of 69.3% from its current price of $30.60.
Amount of Analyst Coverage
SpringWorks Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
20.39% of the float of SpringWorks Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
SpringWorks Therapeutics has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.
Change versus previous month
Short interest in SpringWorks Therapeutics has recently decreased by 3.33%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
SpringWorks Therapeutics does not currently pay a dividend.
Dividend Growth
SpringWorks Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SWTX.

2.9

News and Social Media Coverage

News Sentiment
SpringWorks Therapeutics has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for SpringWorks Therapeutics this week, compared to 2 articles on an average week.
Search Interest
13 people have searched for SWTX on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.
MarketBeat Follows
7 people have added SpringWorks Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SpringWorks Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.43% of the stock of SpringWorks Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SpringWorks Therapeutics are expected to grow in the coming year, from ($5.13) to ($4.66) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SpringWorks Therapeutics is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SpringWorks Therapeutics is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SpringWorks Therapeutics has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SWTX Stock News Headlines

December 9, 2023 | morningstar.com

SpringWorks Therapeutics Inc Ordinary Shares

December 9, 2023 | markets.businessinsider.com

Buy Rating Justified: Springworks Therapeutics’s Ogsiveo Poised to Transform Desmoid Tumor Treatment

December 11, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 8, 2023 | finance.yahoo.com

SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

December 5, 2023 | nasdaq.com

SpringWorks Therapeutics Prices Public Offering Of 9.48 Mln Shares At $29/share

December 5, 2023 | markets.businessinsider.com

Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving

December 5, 2023 | finance.yahoo.com

SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

December 2, 2023 | americanbankingnews.com

FY2024 EPS Estimates for SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Increased by Wedbush

December 11, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

December 1, 2023 | markets.businessinsider.com

Strong Buy: Springworks Therapeutics’ Ogsiveo Poised for Market Success

December 1, 2023 | seekingalpha.com

SpringWorks: Springing Forward On FDA Approval, Right Into Overpriced Territory

December 1, 2023 | americanbankingnews.com

SpringWorks Therapeutics (NASDAQ:SWTX) Trading Up 19.3% on Analyst Upgrade

November 30, 2023 | markets.businessinsider.com

Buy Rating on Springworks Therapeutics with Increased Price Target Following FDA Approval of Ogsiveo

November 29, 2023 | msn.com

SpringWorks Stock (NASDAQ:SWTX) Rallies on FDA’s Rare Tumor Drug Approval

November 29, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Springworks Therapeutics on OGSIVEO’s Superior Efficacy and FDA Approval

November 29, 2023 | msn.com

SpringWorks stock on track for record gain after FDA approves first treatment for rare type of aggressive tumors

November 29, 2023 | msn.com

SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug

November 29, 2023 | finance.yahoo.com

SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 28, 2023 | seekingalpha.com

SpringWorks Therapeutics: Surging On Ogsiveo Approval, Long-Term Outlook Remains Unclear

November 28, 2023 | msn.com

SpringWorks Catapults 24% On A 'Watershed Moment' In Cancer Treatment

November 28, 2023 | msn.com

SpringWorks to charge $29K/month for newly approved drug: report

November 28, 2023 | finance.yahoo.com

SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment

November 28, 2023 | markets.businessinsider.com

Buy Rating for Springworks Therapeutics on Strong FDA Approval and Market Potential

November 28, 2023 | reuters.com

SpringWorks' non-cancerous tumor drug to be priced at $29,000 per month in US

November 28, 2023 | msn.com

Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

November 28, 2023 | markets.businessinsider.com

FDA Approves SpringWorks Therapeutics' Lead Therapy As First For Subtype Of Soft Tissue Sarcomas

November 28, 2023 | msn.com

SpringWorks Therapeutics’ stock jumps after FDA approves first treatment for rare type of aggressive tumors

See More Headlines

Receive SWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SpringWorks Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SWTX
CUSIP: N/A
CIK: 1773427
Web: www.springworkstx.com
Phone: 203-883-9490
Fax: N/A
Employees: 227
Year Founded: 2017

Price Target and Rating

Average Stock Price Target: $51.80
High Stock Price Target: $64.00
Low Stock Price Target: $41.00
Potential Upside/Downside: +64.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-277,420,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.82%
Return on Assets: -55.85%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.60
Quick Ratio: 8.60

Sales & Book Value

Annual Sales: $35 million
Price / Sales: 56.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.95 per share
Price / Book: 3.52

Miscellaneous

Outstanding Shares: 62,580,000
Free Float: 57,929,000
Market Cap: $1.97 billion
Optionable: Not Optionable
Beta: 0.78

Social Links

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Saqib Islam J.D. (Age 53)
CEO & Director
Comp: $1.26M
Mr. Francis I. Perier Jr. (Age 63)
M.B.A., Chief Financial Officer
Comp: $710.6k
Dr. Badreddin Edris Ph.D. (Age 36)
Chief Operating Officer
Comp: $998.61k
Dr. L. Mary Smith PH.D. (Age 56)
Chief Development Officer
Comp: $817.17k
Mr. Bhavesh Ashar (Age 57)
Chief Commercial Officer
Comp: $729.62k
Mr. Michael P. Nofi (Age 52)
Chief Accounting Officer
Mr. Tai-An Lin Ph.D.
Chief Scientific Officer
Ms. Kim Diamond
Vice President of Communications & Investor Relations
Mr. Herschel S. Weinstein J.D. (Age 67)
General Counsel & Secretary
Comp: $568.64k
Mr. Daniel J. Pichl (Age 40)
Chief People Officer
Comp: $428.51k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell SpringWorks Therapeutics stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SpringWorks Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SWTX shares.
View SWTX analyst ratings or view top-rated stocks.
What is SpringWorks Therapeutics' stock price target for 2024?: 4 equities research analysts have issued 1-year price objectives for SpringWorks Therapeutics' shares. Their SWTX share price targets range from $41.00 to $64.00. On average, they expect the company's stock price to reach $51.80 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price.
View analysts price targets for SWTX or view top-rated stocks among Wall Street analysts.
How have SWTX shares performed in 2023?: SpringWorks Therapeutics' stock was trading at $26.01 at the beginning of 2023. Since then, SWTX shares have increased by 17.6% and is now trading at $30.60.
View the best growth stocks for 2023 here.
When is SpringWorks Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our SWTX earnings forecast.
How were SpringWorks Therapeutics' earnings last quarter?: SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($1.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.31) by $0.04.
What ETFs hold SpringWorks Therapeutics' stock?: ETFs with the largest weight of SpringWorks Therapeutics (NASDAQ:SWTX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), First Trust Innovation Leaders ETF (ILDR) and ALPS Medical Breakthroughs ETF (SBIO).Virtus LifeSci Biotech Clinical Trials ETF (BBC).

What other stocks do shareholders of SpringWorks Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other SpringWorks Therapeutics investors own include Axsome Therapeutics (AXSM), Dicerna Pharmaceuticals (DRNA), Johnson & Johnson (JNJ), Albireo Pharma (ALBO), Gilead Sciences (GILD), Sunrun (RUN), Alnylam Pharmaceuticals (ALNY), Aptevo Therapeutics (APVO), Bristol-Myers Squibb (BMY) and BioXcel Therapeutics (BTAI).
When did SpringWorks Therapeutics IPO?: (SWTX) raised $126 million in an initial public offering on Friday, September 13th 2019. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are SpringWorks Therapeutics' major shareholders?: SpringWorks Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Fiera Capital Corp (1.43%), JPMorgan Chase & Co. (0.91%), Northern Trust Corp (0.83%), Charles Schwab Investment Management Inc. (0.68%) and Massachusetts Financial Services Co. MA (0.65%). Insiders that own company stock include Badreddin Edris, Bain Capital Life Sciences Inv, Daniel Pichl, Julie Hambleton, L Mary Smith, Orbimed Advisors Llc, Saqib Islam and Stephen P Squinto.
View institutional ownership trends.
How do I buy shares of SpringWorks Therapeutics?: Shares of SWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does SpringWorks Therapeutics have any subsidiaries?: The following companies are subsidiares of SpringWorks Therapeutics: SpringWorks Subsidiary 1 Inc, SpringWorks Subsidiary 2 Inc, SpringWorks Subsidiary 3 Inc, SpringWorks Subsidiary 4 Inc, SpringWorks Therapeutics LLC, and SpringWorks Therapeutics Operating Company Inc..
Read More

This page (NASDAQ:SWTX) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

SpringWorks Therapeutics (SWTX) Stock Price, News & Analysis

SpringWorks Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About SpringWorks Therapeutics Stock (NASDAQ:SWTX)

SWTX Stock Price History

SWTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

SWTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™